Authority for allotment of New Shares

AI SummaryClose X

Allergy Therapeutics plc is considering an equity raise to facilitate a potential dual listing on the Hong Kong Stock Exchange, expected in the first half of 2026. To enable this, the company is seeking shareholder approval at a general meeting on December 29, 2025, to allot up to 610,000,000 new ordinary shares, representing approximately 10% of current issued share capital, and to disapply pre-emption rights. Funds raised would support the development of allergy treatments and general corporate purposes, including working capital needs prior to the Hong Kong listing.

Disclaimer*

UK 100

Latest directors dealings